Asenapine exerts distinctive regional effects on ionotropic glutamate receptor subtypes in rat brain

Synapse

Volumn 63, Issue 5, 2009, Pages 413-420

  Tarazi, Frank I ^a,b,f   Yong, Kee Choi ^a,b   Gardner, Matthew ^a   Wong, Erik H F ^c,e   Henry, Brian ^d   Shahid, Mohammed ^d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c PFIZER INC   (United States)

^d Schering Plough Research Institute   (United Kingdom)

^e ASTRAZENECA   (United Kingdom)

^f MCLEAN HOSPITAL   (United States)

Author keywords

Asenapine; Caudate putamen; Frontal cortex; Glutamate receptor; Hippocampus

Indexed keywords

AMPA RECEPTOR; ASENAPINE; DIZOCILPINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CAUDATE NUCLEUS; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FOREBRAIN; FRONTAL CORTEX; HIPPOCAMPUS; MALE; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PRIORITY JOURNAL; PUTAMEN; RAT; REPEAT PROCEDURE;

ANIMALS; ANTIPSYCHOTIC AGENTS; AUTORADIOGRAPHY; BINDING SITES; BRAIN; BRAIN CHEMISTRY; DIZOCILPINE MALEATE; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID ANTAGONISTS; GLYCINE; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; MALE; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, AMPA; RECEPTORS, N-METHYL-D-ASPARTATE; REGRESSION ANALYSIS; TRITIUM;

EID: 66049107219     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20618     Document Type: Article

References (45)

1. Aghajanian GK, Marek GJ. 2000. Serotonin model of schizophrenia: Emerging role of glutamate mechanisms. Brain Res Brain Res Rev 31:302-312.
2. Ariano MA, Larson ER, Noblett KL, Sibley DR, Levine MS. 1997. Coexpression of striatal dopamine receptor subtypes and excitatory amino acid subunits. Synapse 26:400-414.
3. Balaban P, Chistiakova M, Malyshev A, Volgushev M. 2004. Dependence of calcium influx in neocortical cells on temporal structure of depolarization, number of spikes, and blockade of NMDA receptors. J Neurosci Res 76:481-487.
4. Baldessarini RJ, Tarazi FI. 2005. Pharmacotherapy of psychosis and mania. In: Brunton LL, Lazo JS, Parker KL, editors. Goodman and Gilman's the pharmacological basis of therapeutics. New York, NY: McGraw-Hill. p 461-500.
5. Bredt DS, Nicoll RA. 2003. AMPA receptor trafficking at excitatory synapses. Neuron 40:361-379.
6. Carlsson A, Waters N, Holm-Waters S, Tedroff J, Nilsson M, Carlsson ML. 2001. Interactions between monoamines, glutamate, and GABA in schizophrenia: New evidence. Annu Rev Pharmacol Toxicol 41:237-260. (Pubitemid 32385889)
7. Carone FA, Ganote CE. 1975. D-serine nephrotoxicity. The nature of proteinuria, glucosuria, and aminoaciduria in acute tubular necrosis. Arch Pathol 99:658-662.
8. Coyle JT, Tsai G. 2004. The NMDA receptor glycine modulatory site: A therapeutic target for improving cognition and reducing negative symptoms in schizophrenia. Psychopharmacology (Berl) 174:32-38.
9. Ding DC, Gabbott PL, Totterdell S. 2001. Differences in the laminar origin of projections from the medial prefrontal cortex to the nucleus accumbens shell and core regions in the rat. Brain Res 917:81-89.
10. Franberg O, Wiker C, Marcus MM, Konradsson A, Jardemark K, Schilstrom B, Shahid M, Wong EH, Svensson TH. 2008. Asenapine, a novel psychopharmacologic agent: Preclinical evidence for clinical effects in schizophrenia. Psychopharmacology (Berl) 196: 417-429.
11. Gao XM, Sakai K, Roberts RC, Conley RR, Dean B, Tamminga CA. 2000. Ionotropic glutamate receptors and expression of N-methyl-D-aspartate receptor subunits in subregions of human hippocampus: Effects of schizophrenia. Am J Psychiatry 157:1141-1149. (Pubitemid 30432497)
12. Goff DC, Coyle JT. 2001. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 158:1367-1377.
13. Goff DC, Leahy L, Berman I, Posever T, Herz L, Leon AC, Johnson SA, Lynch G. 2001. A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia. J Clin Psychopharmacol 21:484-487.
14. Greene WH. 2000. Econometric analysis. Upper Saddle River: Prentice Hall.
15. Hollmann M, Heinemann S. 1994. Cloned glutamate receptors. Annu Rev Neurosci 17:31-108.
16. Huang M, Li Z, Dai J, Shahid M, Wong EH, Meltzer HY. 2008. Asenapine increases dopamine, norepinephrine, and acetylcholine efflux in the rat medial prefrontal cortex and hippocampus. Neuropsychopharmacology 33:2934-2945.
17. Huettner JE. 2003. Kainate receptors and synaptic transmission. Prog Neurobiol 70:387-407.
18. Javitt DC, Zukin SR. 1991. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148:1301-1308.
19. Javitt DC, Zylberman I, Zukin SR, Heresco-Levy U, Lindenmayer JP. 1994. Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiatry 151:1234-1236.
20. Kew JN, Kemp JA. 2005. Ionotropic and metabotropic glutamate receptor structure and pharmacology. Psychopharmacology (Berl) 179:4-29.
21. McCoy L, Cox C, Richfield EK. 1998. Antipsychotic drug regulation of AMPA receptor affinity states and GluR1, GluR2 splice variant expression. Synapse 28:195-207.
22. 3H]glycine binding sites in rat brain by quantitative receptor autoradiography. Neuroscience 35:653-668.
23. McIntyre R, Hirschfield R, Calabrese J, Panagides J, Szegedi A. 2008. Asenapine in bipolar disorder: an overview of the clinical trials in the Olympia program. Int J Neuropsychopharmacol 11:183(S).
24. Meador-Woodruff JH, Healy DJ. 2000. Glutamate receptor expression in schizophrenic brain. Brain Res Brain Res Rev 31:288-294.
25. Mohn AR, Gainetdinov RR, Caron MG, Koller BH. 1999. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 98:427-436.
26. Ozawa S, Kamiya H, Tsuzuki K. 1998. Glutamate receptors in the mammalian central nervous system. Prog Neurobiol 54:581-618.
27. Paxinos G, Watson C. 1997. The rat brain in stereotaxic coordinates. San Diego, CA: Academic Press.
28. Potkin SG, Cohen M, Panagides J. 2007. Efficacy and tolerability of asenapine in acute schizophrenia: A placebo- and risperidone-controlled trial. J Clin Psychiatry 68:1492-1500.
29. Riva MA, Tascedda F, Lovati E, Racagni G. 1997. Regulation of NMDA receptor subunit messenger RNA levels in the rat brain following acute and chronic exposure to antipsychotic drugs. Brain Res Mol Brain Res 50:136-142.
30. Schmidt WJ, Bubser M. 1989. Anticataleptic effects of the N-methyl-D-aspartate antagonist MK-801 in rats. Pharmacol Biochem Behav 32:621-623.
31. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, Leysen JE. 1996. Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding. Psychopharmacology (Berl) 124:57-73.
32. Shahid M, Walker GB, Zorn SH, Wong EH. 2008. Asenapine: A novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol [Epub ahead of print].
33. Spurney CF, Baca SM, Murray AM, Jaskiw GE, Kleinman JE, Hyde TM. 1999. Differential effects of haloperidol and clozapine on ionotropic glutamate receptors in rats. Synapse 34:266-276.
34. Tarazi FI, Florijn WJ, Creese I. 1996. Regulation of ionotropic glutamate receptors following subchronic and chronic treatment with typical and atypical antipsychotics. Psychopharmacology (Berl) 128:371-379.
35. Tarazi FI, Baldessarini RJ, Kula NS, Zhang K. 2003. Long-term effects of olanzapine, risperidone, and quetiapine on ionotropic glutamate receptor types: Implications for antipsychotic drug treatment. J Pharmacol Exp Ther 306:1145-1151.
36. Tarazi FI, Moran-Gates T, Gardner MP, Graulich A, Lamy C, Liegeois JF. 2007. Long-term effects of JL 13, a potential atypical antipsychotic, on ionotropic glutamate receptors. JMol Neurosci 32: 192-198.
37. Tarazi FI, Moran-Gates T, Wong EH, Henry B, Shahid M. 2008a. Asenapine induces differential regional effects on serotonin receptor subtypes. J Psychopharmacol [Epub ahead of print].
38. Tarazi FI, Moran-Gates T, Wong EH, Henry B, Shahid M. 2008b. Differential regional and dose-related effects of asenapine on dopamine receptor subtypes. Psychopharmacology (Berl) 198:103-111.
39. Tarsy D, Baldessarini RJ, Tarazi FI. 2002. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs 16:23-45.
40. Tascedda F, Lovati E, Blom JM, Muzzioli P, Brunello N, Racagni G, Riva MA. 1999. Regulation of ionotropic glutamate receptors in the rat brain in response to the atypical antipsychotic seroquel (quetiapine fumarate). Neuropsychopharmacology 21:211-217.
41. Tascedda F, Blom JM, Brunello N, Zolin K, Gennarelli M, Colzi A, Bravi D, Carra S, Racagni G, Riva MA. 2001. Modulation of glutamate receptors in response to the novel antipsychotic olanzapine in rats. Biol Psychiatry 50:117-122.
42. Tsai G, Coyle JT. 2002. Glutamatergic mechanisms in schizophrenia. Annu Rev Pharmacol Toxicol 42:165-179.
43. Tsai G, Yang P, Chung LC, Lange N, Coyle JT. 1998. D-Serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 44:1081-1089.
44. Winer BJ, Brown DR, Michels KM. 1991. Statistical principles in experimental drug design. New York, NY: McGraw Hill.
45. Yoshida Y, Ono T, Kizu A, Fukushima R, Miyagishi T. 1991. Striatal N-methyl-D-aspartate receptors in haloperidol-induced catalepsy. Eur J Pharmacol 203:173-180.